Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center

To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hematology (Luxembourg) Ročník 29; číslo 1; s. 2431958
Hlavní autoři: Xu, Shuiqing, Chen, Wenming, Li, Yanchen
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Taylor & Francis Group 01.12.2024
Témata:
Adult
Aged
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
daratumumab-based
daratumumab-free
Female
Humans
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
newly-diagnosed
paraskeletal plasmacytomas
Plasmacytoma - diagnosis
Plasmacytoma - drug therapy
Plasmacytoma - mortality
Retrospective Studies
risk factors
risk factors
Multiple myeloma
overall survival
daratumumab-free
newly-diagnosed
daratumumab-based
paraskeletal plasmacytomas
efficacy
ISSN:1607-8454, 1607-8454
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups. The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88,  = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01,  = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups,  = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27,  = 0.002). The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.
AbstractList Objective To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).Methods The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.Results The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).Conclusions The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.
To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).OBJECTIVETo analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.METHODSThe medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups.The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).RESULTSThe results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88, p = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01, p = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups, P = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27, P = 0.002).The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.CONCLUSIONSThe results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.
To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups. The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88,  = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01,  = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups,  = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27,  = 0.002). The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.
Author Li, Yanchen
Xu, Shuiqing
Chen, Wenming
Author_xml – sequence: 1
  givenname: Shuiqing
  surname: Xu
  fullname: Xu, Shuiqing
  organization: Beijing Chaoyang Integrative Medicine Rescue and First Aid Hospital, Beijing, People’s Republic of China
– sequence: 2
  givenname: Wenming
  surname: Chen
  fullname: Chen, Wenming
  organization: Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China
– sequence: 3
  givenname: Yanchen
  surname: Li
  fullname: Li, Yanchen
  organization: Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39589101$$D View this record in MEDLINE/PubMed
BookMark eNpNkctu1TAQhi1URC_wCCAv2aTYsZPjsEMFSqVKbGBtTezxwcW5YDut8hi8MU7PacXGl5lP38j-z8nJOI1IyFvOLjlT7ANv2U7JRl7WrC6LFLxr1AtyttWrrXHy3_mUnKd0x1hdsx17RU5FYTvO-Bn5-xki5GVYBuirHhJaGnHvBxypmyId8SGs1HrYj9PWG5aQ_RyQDiuGaQA6Q_Y45kQffP5VbhHSbwyYIdA5QBrArLlw6SOFIs5xSjOa7O-RprzYlfqxNJIf98Vpigjja_LSQUj45rhfkJ9fv_y4-lbdfr--ufp0WxmxY7lqVCuM6XeqdbyzSjnkzDEhnGVoetv2wgk0Xe1E3THprHGNKq8HxJq12DXigtwcvHaCOz1HP0Bc9QRePxamuNcQszcBdWcdSgApLEoprQXHa8esstz24IQtrvcH1xynPwumrAefDIYAI05L0oKLWskdZ6yg747o0g9onwc_RVKA5gCY8lkpontGONNb9Poper1Fr4_Ri38i96VK
Cites_doi 10.1038/s41375-019-0660-0
10.1111/j.1600-0609.2004.00331.x
10.1007/s40262-023-01240-8
10.1111/bjh.13383
10.1038/s41375-019-0435-7
10.3324/haematol.2013.094409
10.3892/ol.2024.14381
10.1016/j.clml.2014.12.013
10.1016/j.clml.2016.08.010
10.1016/j.rcl.2015.12.008
10.1016/S1470-2045(14)70442-5
10.1007/s12253-019-00725-x
10.1016/j.clml.2022.04.014
10.1038/s41408-022-00730-5
10.1016/j.tranon.2022.101465
10.1038/leu.2011.29
10.3324/haematol.2019.219139
10.1111/bjh.13382
10.1038/sj.leu.2404284
10.1111/ejh.12377
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.1080/16078454.2024.2431958
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1607-8454
ExternalDocumentID oai_doaj_org_article_9dfe4aa43de444ddaf12f0d8d1dbaf3d
39589101
10_1080_16078454_2024_2431958
Genre Journal Article
GroupedDBID ---
002
0YH
1~B
29I
36B
4.4
53G
AAFWJ
AALUX
AAYXX
ABDBF
ACGEJ
ACUHS
ADCVX
ADXPE
AENEX
AFPKN
AIJEM
AJWEG
ALMA_UNASSIGNED_HOLDINGS
AQTUD
ARJSQ
BLEHA
BOHLJ
CCCUG
CITATION
CS3
DU5
E01
EAP
EBC
EBD
EBS
EMB
EMK
EMOBN
EPL
ESX
F5P
GROUPED_DOAJ
H13
HCLVR
HZ~
KTTOD
M4Z
MV1
OK1
P76
P7A
P7B
QZIEQ
SV3
TDBHL
TFL
TFW
TUS
~XQ
5VS
ABUPF
AGYJP
AWYRJ
CAG
CGR
COF
CUY
CVF
CZDIS
DRXRE
ECM
EIF
EJD
M46
NPM
7X8
ID FETCH-LOGICAL-c370t-5863ccb786f19d88fe10f033fd0ecbd6b3f3ec92f32904fdcf58207aee206e953
IEDL.DBID DOA
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001364306700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1607-8454
IngestDate Fri Oct 03 12:35:36 EDT 2025
Fri Jul 11 14:48:55 EDT 2025
Mon Jul 21 06:05:12 EDT 2025
Sat Nov 29 03:45:24 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords risk factors
Multiple myeloma
overall survival
daratumumab-free
newly-diagnosed
daratumumab-based
paraskeletal plasmacytomas
efficacy
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c370t-5863ccb786f19d88fe10f033fd0ecbd6b3f3ec92f32904fdcf58207aee206e953
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/9dfe4aa43de444ddaf12f0d8d1dbaf3d
PMID 39589101
PQID 3132847100
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_9dfe4aa43de444ddaf12f0d8d1dbaf3d
proquest_miscellaneous_3132847100
pubmed_primary_39589101
crossref_primary_10_1080_16078454_2024_2431958
PublicationCentury 2000
PublicationDate 2024-Dec
PublicationDateYYYYMMDD 2024-12-01
PublicationDate_xml – month: 12
  year: 2024
  text: 2024-Dec
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Hematology (Luxembourg)
PublicationTitleAlternate Hematology
PublicationYear 2024
Publisher Taylor & Francis Group
Publisher_xml – name: Taylor & Francis Group
References e_1_3_2_16_1
e_1_3_2_9_1
e_1_3_2_17_1
e_1_3_2_18_1
e_1_3_2_7_1
e_1_3_2_19_1
e_1_3_2_2_1
e_1_3_2_20_1
e_1_3_2_10_1
e_1_3_2_21_1
e_1_3_2_11_1
e_1_3_2_22_1
e_1_3_2_6_1
e_1_3_2_12_1
e_1_3_2_5_1
e_1_3_2_13_1
e_1_3_2_4_1
e_1_3_2_14_1
e_1_3_2_3_1
e_1_3_2_15_1
Rosiñol L (e_1_3_2_8_1) 2012; 120
References_xml – ident: e_1_3_2_6_1
  doi: 10.1038/s41375-019-0660-0
– ident: e_1_3_2_22_1
  doi: 10.1111/j.1600-0609.2004.00331.x
– ident: e_1_3_2_9_1
  doi: 10.1007/s40262-023-01240-8
– ident: e_1_3_2_16_1
  doi: 10.1111/bjh.13383
– ident: e_1_3_2_19_1
  doi: 10.1038/s41375-019-0435-7
– ident: e_1_3_2_17_1
  doi: 10.3324/haematol.2013.094409
– ident: e_1_3_2_10_1
  doi: 10.3892/ol.2024.14381
– ident: e_1_3_2_15_1
  doi: 10.1016/j.clml.2014.12.013
– ident: e_1_3_2_5_1
  doi: 10.1016/j.clml.2016.08.010
– ident: e_1_3_2_11_1
  doi: 10.1016/j.rcl.2015.12.008
– ident: e_1_3_2_12_1
  doi: 10.1016/S1470-2045(14)70442-5
– ident: e_1_3_2_18_1
  doi: 10.1007/s12253-019-00725-x
– volume: 120
  start-page: 1589
  issue: 8
  year: 2012
  ident: e_1_3_2_8_1
  article-title: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. blood
  publication-title: The Journal of the American Society of Hematology
– ident: e_1_3_2_21_1
  doi: 10.1016/j.clml.2022.04.014
– ident: e_1_3_2_7_1
  doi: 10.1038/s41408-022-00730-5
– ident: e_1_3_2_20_1
  doi: 10.1016/j.tranon.2022.101465
– ident: e_1_3_2_2_1
  doi: 10.1038/leu.2011.29
– ident: e_1_3_2_3_1
  doi: 10.3324/haematol.2019.219139
– ident: e_1_3_2_14_1
  doi: 10.1111/bjh.13382
– ident: e_1_3_2_13_1
  doi: 10.1038/sj.leu.2404284
– ident: e_1_3_2_4_1
  doi: 10.1111/ejh.12377
SSID ssj0022070
Score 2.3515239
Snippet To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data...
To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).OBJECTIVETo...
Objective To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).Methods...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
StartPage 2431958
SubjectTerms Adult
Aged
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
daratumumab-based
daratumumab-free
Female
Humans
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
newly-diagnosed
paraskeletal plasmacytomas
Plasmacytoma - diagnosis
Plasmacytoma - drug therapy
Plasmacytoma - mortality
Retrospective Studies
risk factors
Title Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
URI https://www.ncbi.nlm.nih.gov/pubmed/39589101
https://www.proquest.com/docview/3132847100
https://doaj.org/article/9dfe4aa43de444ddaf12f0d8d1dbaf3d
Volume 29
WOSCitedRecordID wos001364306700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1607-8454
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022070
  issn: 1607-8454
  databaseCode: DOA
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVAWR
  databaseName: Taylor & Francis Open Access
  customDbUrl:
  eissn: 1607-8454
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022070
  issn: 1607-8454
  databaseCode: 0YH
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
– providerCode: PRVAWR
  databaseName: Taylor and Francis Online Journals
  customDbUrl:
  eissn: 1607-8454
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022070
  issn: 1607-8454
  databaseCode: TFW
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtKKWXkr43SYMKvbrRy5aUW57kkIYeWtiezOgFobE37HoD-zPyj6PxI-RSeulFB8nIkmbs-TQafUPIVwCtvSpFIaSUhbKVLyABL3yC5EqduBt4Zi_11ZWZz-2PJ6m-MCZsoAceFu7AhhQVgJIhKqVCgMRFYsEEHhwkGfDvy7SdNlPjVitXsem-jmEHyKJmVO9DEbnIRtNijvcnlqgn7P87yuytzfk2eT3CRHo0DO8NeRbbt-Tl9_Eg_B25P0XK7nWzbsAVaIkCxRQLTWxpRqE0Y-WbDQ1DGF1um8IGabOJN4sG6EinuqLoh6XI_736kw1QRuL0NuPpBvymw8ihQwq54265mG5k0p6Pll63uQHdDLlPjO-My_fk1_nZz5OLYsyuUHipWVeUppLeO22qxG0wJkXOEpMyBRa9C5WTSUZvRZLCMpWCT2VGCxpiFKyKtpQfyFa7aOMnQqEC5YHZyFSGX9I5g5wynEepRHCimpFv00rXtwOJRs1HbtJJNDWKph5FMyPHKI_Hh5EDu6_ImlGPmlH_SzNm5MskzTp_M3gQAm1crFc10lWiVWZsRj4OYn58lbSYZ5Hxnf8xhF3yCqc1hL_ska1uuY6fyQt_112vlvvkOft9kUs9N_u9-j4Ae2P3Eg
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Daratumumab-based+regimen+for+newly+diagnosed+multiple+myeloma+patients+with+paraskeletal+plasmacytomas%3A+a+retrospective+study+in+a+single+center&rft.jtitle=Hematology+%28Luxembourg%29&rft.au=Shuiqing+Xu&rft.au=Wenming+Chen&rft.au=Yanchen+Li&rft.date=2024-12-01&rft.pub=Taylor+%26+Francis+Group&rft.eissn=1607-8454&rft.volume=29&rft.issue=1&rft_id=info:doi/10.1080%2F16078454.2024.2431958&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_9dfe4aa43de444ddaf12f0d8d1dbaf3d
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1607-8454&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1607-8454&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1607-8454&client=summon